Provided below are:
● the table of contents (p.1) ● information about IPQ (p.2), and ● the editor’s note on the issue (p.3).
The December issue provides updates on FDA/CDER’s Office of Generics Drugs and Office of Pharmaceutical Quality – what have been the key areas of focus over the past year and what the top priorities are going forward. The third story crosses the Atlantic to explore how Brexit is impacting the MHRA in the medicines arena and what the agency is doing to prepare for what may happen.